Nexien Biopharma Inc Net Income per Employee (NXEN), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Nexien Biopharma Inc   (NXEN)
 

Nexien Biopharma Inc Net Income per Employee

NXEN's Quarterly Results, Trends, Rankings, Statistics
Nexien Biopharma Inc recorded a cumulative net loss of $0 million during 12 month ending in the third quarter 2025.
The Healthcare sector has seen employees of 63 other companies achieving higher income per employee. While Nexien Biopharma Inc 's total ranking has deteriorated compared to the previous quarter from 2412 to 2433.


What is Income per Employee Ratio?






NXEN Net Income per Employee (Mar 31 2025)
III. Quarter
(Dec 31 2024)
II. Quarter
(Sep 30 2024)
I. Quarter
(Jun 30 2024)
IV. Quarter
(Mar 31 2024)
III. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -14,468 -16,243 -15,092 -18,393 -18,937
NXEN's Total Ranking # 2433 # 2412 # 2387 # 0 # 0
Seq. Net Income Change - - - - -


NXEN Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 64
Healthcare Sector # 210
Overall Market # 2433

Net Income per Employee Statistics
High Average Low
$ -14,468 $ -123,478 $ -451,836
(Mar 31 2025)   (Sep 30 2019)







Companies with similar Income per Employee for 12 month ending Mar 31 2025, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2025Number of Employees Mar 31 2025


Date modified: 2026-09-08T15:11:31+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.